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SUMMARY
Cervical cancer remains an important public health 
problem in developing countries where over 80% of 
the global burden occurs annually but screening has 
been ineffective. In a polygamous country like Ghana 
with a high incidence of cervical cancer but no national 
screening program, the Human Papilloma Virus (HPV)
vaccine presents a unique opportunity to reduce the 
burden of HPV infection and cervical cancer in Ghana-
ian women. The evidence so far indicates that the vac-
cines are safe and efficacious. Although routine HPV 
vaccination of girls raises several religious, political, 
socioeconomic and ethical challenges, the emphasis of 
this paper will be on addressing the ethical challenges 
using the principles of autonomy, beneficence, non-
maleficence and justice as a framework.  Parental au-
tonomy can be preserved with judicious exemptions for 
those who decline the vaccine on religious and philo-
sophical grounds. This promotes public health without 
trampling parental authority. Routine HPV vaccination 
confers several benefits to individuals and society by 
preventing HPV infection. Instead of causing harm; it 
reduces harm by preventing the development of about 
70% of cervical cancers and removing the negative 
physical and psychological impact of a cervical cancer 
diagnosis. It also has the potential to reduce the dispari-
ties in cervical cancer rates and its cost effectiveness 
will ensure considerable cost savings in terms of the 
money spent on diagnosis and treatment. Consequent-
ly, the HPV vaccine is an important public health 
landmark and achievement in women’s health that 
must be heralded, especially in developing countries 
where the bulk of the disease and death occur. 
Keywords: Human papilloma virus, vaccination, pre-
adolescent girls, Ghana
INTRODUCTION 
Of all cancers, cervical cancer is the one that glaringly 
reflects global health inequity. Over 80% of the yearly 
500,000 new cervical cancer cases and 280,000 cervi-
cal cancer deaths worldwide occur in developing coun-
tries. The highest burden and mortality associated with 
cervical cancer worldwide is in Sub-Saharan Africa 
where a woman has a 21% chance of surviving while a 
woman in the United States has a 70% chance of sur-
viving.1 Despite this, there are few, if any, primary and 
secondary prevention programs to combat cervical 
cancer in Sub-Saharan Africa.  
In Ghana, cervical cancer constitutes about 57.8% of 
all gynaecological cancers.2 It is the second most 
common cancer in women with an estimated incidence 
of 19.4 per 100,000. It is also the second most common 
cancer in women aged 15 to 44 years in Ghana. Every 
year, 1958 women are diagnosed with cervical cancer 
and 1572 die from it in Ghana.3
While the WHO estimates the Human Papillomavirus 
(HPV) prevalence in the West African sub-region, in-
cluding Ghana, at 16.5% of women, a study estimating 
HPV prevalence among a sample of women attending a 
gynaecology outpatient clinic in Accra, Ghana found a 
crude HPV prevalence of 10.7%.4
Although cervical cancer screening has been effective 
in reducing morbidity and mortality over the past 50 
years in many high income countries, this has not been 
the case in low income countries because of the ab-
sence of effective cervical cancer screening programs.5
Despite the effectiveness of the Pap smear in reducing 
the burden of cervical cancer, it has significant limita-
tions, the high false negative rate being the most criti-
cal. The limitations associated with the Pap smear be-
come even more critical in a low income country such 
as Ghana where there is a dearth of qualified personnel 
needed for sample collection, slide preparation and 
slide interpretation. In addition to the Pap smear, Visu-
al inspection with acetic acid (VIA) has been has been 
available in Ghana from 2001. This involves a single 
visit with visual inspection with acetic acid of the cer-
vix and cryotherapy for lesions that are pre-cancerous.
June 2010 Ama K. Edwin            Routine HPV vaccination
71
Although there is evidence that a single visit VIA of 
the cervix is practical and sustainable and should there-
fore form part of a national program to prevent and 
control cervical cancer, “the lack of health infrastruc-
ture and political will has prevented scale-up to a na-
tional programme in Ghana”6 Cervical cancer screen-
ing therefore may have a limited impact in such a pop-
ulation. On the other hand, primary prevention can be a 
more effective way of reducing the burden of cervical 
cancer by minimizing exposure to the HPV infection 
and utilizing routine HPV immunization. 
Although routine HPV vaccination of girls raises sev-
eral religious, political, socioeconomic and ethical 
challenges, the emphasis of this paper will be on ad-
dressing the ethical challenges using the principles of 
autonomy, beneficence, non-maleficence and justice as 
a framework. As argued below, for those against rou-
tine HPV immunization claim it violates parental au-
tonomy, involves risks which are not offset by the ben-
efits of vaccination, causes more harm than good and is 
unjust. For those in favor, it enhances parental autono-
my, is beneficial, reduces harm and is just. 
In a polygamous country with a high incidence of cer-
vical cancer but no national screening program, the 
HPV vaccine presents a unique opportunity to reduce 
the burden of HPV infection and consequently cervical 
cancer in Ghanaian women. This paper aims to show 
that the Centers for Disease Control and Prevention 
(CDC)’s Advisory Committee on Immunization Prac-
tices’ (ACIP) recommendation of routine vaccination 
of females aged 11–12 years7 is a policy that can be 
justifiably adopted as a more effective way of reducing 
the public health burden of cervical cancer in Ghana 
provided the subtypes in the vaccines are effective in 
the Ghanaian population.
THE CASE AGAINST ROUTINE HPV 
VACCINATION 
Autonomy 
Autonomy goes hand in hand with self-determination.8
By extension, parents should have a choice in deter-
mining what is done to their children. Parental autono-
my is therefore a core issue of concern in routine HPV 
vaccination.9 Unlike other mandatory childhood im-
munizations such as polio and measles, HPV is not a 
contagious disease. Since it is transmitted sexually, 
placing it on the same level as other contagious diseas-
es is unjustifiable.  Although there are exemptions to 
vaccine requirements for parents who do not want their 
children vaccinated based on religious and philosophi-
cal grounds, this imposes an unfair burden on parents 
who want to do so. In addition, the protection is in-
complete - the vaccine gives protection against the high 
risk HPV types responsible for 70% of cervical can-
cers.10 As a result, women would still need other pre-
ventive measures against cervical cancer. Routine HPV 
vaccination for preteen girls is therefore an unneces-
sary measure that ends up trampling parental autono-
my.
Beneficence 
Beneficence is the moral obligation to act for the bene-
fit of others, including the prevention of harms.8 This 
means maximizing potential benefits to individuals and 
society while minimizing potential harms. Although 
there are benefits to the HPV vaccine such as preven-
tion of HPV infection, the risks of routine HPV vac-
cination are not offset by the benefits. There are still 
many unknowns for it to be considered as a credible 
extension to the abstinence-only campaign. The vac-
cine was not tested on enough preteen girls to make it a 
routine requirement.  Of the 25,000 participants in the 
clinical trial, only 1184 were preteen girls.10 Other un-
knowns include not knowing if and when boosters will 
be required; not knowing all the side effects and long 
term effects of the vaccine including its effects on fer-
tility and pregnancy. 
Non-maleficence
Non-maleficence is the obligation of not inflicting 
harm on others.8 By making HPV vaccination routine, 
several harms could be inflicted not only on young 
girls but on society as a whole.9 Routine HPV vaccina-
tion will encourage premarital sex in adolescents and 
give them tacit permission to engage in risky sexual 
behaviours. In addition, because adolescents may not 
fully understand the utility of the HPV vaccine, they 
may over-generalize its protection to include other sex-
ually transmitted infections (STIs) like HIV and there-
fore practice unsafe sex with devastating consequences.  
Young people who may want to abstain from sex may 
also be pressured by their peers to engage in premarital 
sex due to a false sense of protection.
Adolescents are developmentally vulnerable to risky 
behavior including experimenting with sex without full 
understanding of the consequences. To counteract this, 
they need to know emphatically that abstinence is the 
only foolproof method against STIs and unwanted 
pregnancies. Moreover, some people may not under-
stand that the vaccine does not give full protection 
against cervical cancer and may therefore not partici-
pate in screening programs. There is also the danger 
that vaccination and screening may be seen as mutually 
exclusive rather than complementary. 
Justice 
The cost effectiveness of routine HPV vaccination is 
questionable. Since health resource is not unlimited, 
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money spent on routine vaccination would be better 
spent addressing other health problems and making Pap 
smears available to those who cannot access it. Justice 
denotes fair and equitable treatment,8 thus, the vaccine 
should be available to all who need it. Unfortunately, 
the HPV vaccine is more likely to create health dispari-
ties because there are still questions regarding how 
poor, underserved and hard-to-reach girls, who as 
women are the most vulnerable group to develop cervi-
cal cancer, will receive the 3 doses over a 6 month pe-
riod.10 Moreover, since HPV infection is an STI, it is 
unjust to require that adolescents who plan life-long 
abstinence should be vaccinated. It is also wrong to 
target only females with HPV vaccination, since fe-
males get the infection from males. For justice to be 
served, the vaccine should be given to boys as well. 
THE CASE FOR ROUTINE HPV VAC-
CINATION
Autonomy 
In requiring that the HPV vaccine be given routinely, 
the potential public health benefits of protecting indi-
viduals against HPV infection and consequently reduc-
ing the public health burden of HPV infection and cer-
vical cancer must far outweigh government’s interfer-
ence in parental autonomy. In as much as parental au-
tonomy gives parents the right to make decisions on 
behalf of their children, the State also has an interest in 
protecting the health of children. In the past, mandates 
regarding certain vaccines being given routinely have 
succeeded in reducing infectious diseases and estab-
lishing herd immunity. Although some argue that it is 
unjustified for the State to have a mandate regarding 
routine vaccination of a sexually transmitted infection, 
there is a precedent of routine vaccination against the 
hepatitis B virus, which, like HPV, is a largely sexually 
transmitted infection.11
To maintain parental autonomy, there are exemptions 
for parents who do not want their children vaccinated 
based on religious and philosophical grounds. Further-
more, rather than trample parental autonomy, public 
health officials can enhance parental autonomy by 
making reliable information on HPV and HPV vaccina-
tion readily available to parents. Access to such infor-
mation can motivate parents to be proactive in making 
health care decisions for their children. Parental auton-
omy can therefore be enhanced whether parents partic-
ipate in routine vaccination or opt out because of vari-
ous concerns.
Beneficence 
The benefits of routine HPV vaccination are obvious. 
These include decreased HPV infection, decreased cer-
vical cancer, decreased genital warts and establishing 
herd immunity against HPV. A worldwide test of the 
HPV vaccine with over 11,000 females between 9 – 26 
years showed that it is 100% effective in preventing the 
four HPV strains responsible for 70% of cervical can-
cers and 90% of genital warts.12Routine HPV vaccina-
tion therefore has the potential to drastically reduce the 
public health burden of cervical cancer. Combined with 
cervical cancer screening, routine HPV vaccination 
presents an exceptional opportunity to eradicate cervi-
cal cancer.
In addition, even if a female is abstinent until marriage 
and stays faithful in marriage, she can still be at risk of 
getting HPV because her husband who may not have 
abstained and/or is unfaithful can still transmit HPV to 
her. Furthermore, females who abstain are not exempt 
from sexual violence and therefore HPV exposure. 
Considering that HPV infection occurs in about 43–
44% of women after 3 years of sexual activity and 
many adolescents are sexually active, it makes good 
public health sense to vaccinate preteen girls to protect 
them from HPV infection.13 With regards to if and 
when boosters will be required, although future re-
search is needed to know precisely the long-term effi-
cacy of the vaccine, a recent modelling study indicates 
that the vaccine may remain efficacious for at least 12 
years.14It is therefore likely that the vaccine will protect 
young women throughout the years when they are most 
susceptible to HPV infection.
Non-maleficence
Although non-maleficence is the obligation of not in-
flicting harm on others, it “does not preclude balancing 
potential harms against potential benefits”.15 The prem-
ise that HPV vaccination of preteen girls implies a tacit 
consent to engage in sexual activity is akin to saying 
that letting children wear bicycle helmets when riding 
their bicycles is a tacit consent for them to crash their 
heads. Encouraging prevention is not the same as giv-
ing permission to take health risks. As rightly put by 
Monk and Wiley: “HPV vaccination is not synony-
mous with support and approval of promiscuity rather a 
cry to rally together to eradicate cervical cancer 
worldwide”.16 It is vital that this remarkable public 
health breakthrough is not equated with endorsing ado-
lescent sexual irresponsibility. Rather, it must be seen 
as an essential step in promoting the next generation’s 
health.
There are justifications for targeting preteen girls.11
Firstly, because the vaccine is preventive, and not ther-
apeutic, it has to be given before exposure. As such, by 
targeting this group, we ensure that most young women 
are protected, whether they initiate sex early or late. By 
routinely vaccinating girls at the recommended age and 
before engaging in sexual activity, we have a greater 
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chance of preventing cervical cancer and its impact on 
poor and vulnerable women. Secondly, as seen with the 
initiation of the HBV vaccinations, age-based vaccina-
tions have been more successful than risk-based vac-
cinations. Thirdly, younger adolescents have a better 
immunogenic response than older adolescents. Fourth-
ly, parents and guardians, if they choose, may well use 
HPV vaccination as an opportunity for them to discuss 
their views on sex with their children. 
Similarly, it is unlikely that a mandate for routine HPV 
vaccination will give a false sense of protection from 
STIs and lead to sexual dis-inhibition with decreases in 
safer sex practices. There is no empirical evidence in 
support of this and fear of an STI is not a primary rea-
son for adolescents not to engage in sex.10 In any case, 
it is unlikely that HPV vaccination will undermine 
years of good communication of parental values re-
garding sex and sexuality. Moreover, routine HPV vac-
cination should not lead to an inappropriate decrease in 
cervical cancer screening. Even with routine HPV vac-
cination, cervical cancer screening will still be neces-
sary because some women are already infected and the 
vaccine does not protect against all cervical cancers. 
However, with the availability of the HPV vaccine, 
thousands of new cases of cervical cancer can be pre-
vented every year. 
Justice 
The economic and social burden of HPV infections and 
their sequelae is huge, especially in Ghana where it is 
the second most frequent cancer in women aged 15 to 
44 years (women in the prime of life raising their fami-
lies). Studies show that compared to current cervical 
cancer prevention protocols, “a prophylactic vaccine 
targeting high-risk HPV subtypes decreased cervical 
cancer risk by 46 to 66 per cent and significantly in-
creased quality-adjusted life expectancy”.17 In essence, 
the vaccine is cost-effective. In addition, non-monetary 
cost savings such as the emotional pain and reactions 
associated with an abnormal Pap smear as well as cop-
ing with the invasive treatment of cancerous and pre-
cancerous lesions are very significant. 
Justice requires that the vaccine should be accessible to 
all. In this vein, there are measures in place to ensure 
that the vaccine gets to all those who need it. In Ghana, 
all routine vaccines are given free. As such, unlike 
screening for cervical cancer which is accessible to 
only those who can afford it, routine HPV vaccination 
will decrease health disparities, thereby ensuring that 
justice is done. In addition, even though some people 
may choose a lifetime abstinence lifestyle, there is no 
guarantee that they may not become victims of sexual 
assault. It would therefore be unjust to exclude such 
people. 
Even though routine vaccination is free, the cost of 
introducing the HPV vaccine may depend on source of 
funding and assurance of sustainable funding. This is 
where endorsement by GAVI is crucial. This is particu-
larly important since the HPV vaccine is still too costly 
for those who need it. The support garnered by GAVI 
with the wide availability of the hepatitis B vaccine in 
developing countries testifies to the fact that vaccine 
prices inevitably decline with the rising demand18. Sim-
ilarly, such an initiative by GAVI can significantly 
reduce the cost of the HPV vaccine.
Although vaccinating both girls and boys is the best 
way to achieve herd immunity, there is currently no 
efficacy data available on boys.11 However, it is safe to 
assume that when efficacy is demonstrated with conse-
quent licensing of the vaccine for use in boys, they will 
also be vaccinated. Therefore the argument that not 
giving boys the vaccine now is unjust becomes untena-
ble.
JUSTIFICATION OF ROUTINE HPV 
VACCINATION FOR GHANA
How a society defines a particular situation determines 
the nature of its response. When syphilis was demysti-
fied, addressed with adequate resources and defined as 
a public health rather than a moral problem in the US, 
great strides were made in controlling it.19 In the same 
way, defining HPV infection as a public health rather 
than a moral problem resulting from promiscuity is 
vital for the measures we as a society put in place to 
address it. “Cancer is a public health challenge that 
needs to be conquered; it is not an appropriate venue 
for political or ideological debate”.10
Is routine HPV vaccination an option for Ghana? Yes it 
is, with far more going in favour of this option than 
against it. 
According to the Institute of Medicine (IOM), “Public 
health is what we, as a society, do collectively to assure 
the conditions for people to be healthy”.20 Ensuring 
that preteen girls get the HPV vaccine is in keeping 
with this definition of public health. Routine vaccina-
tions ensure high herd immunity, thereby protecting all 
members of the community including those who cannot 
receive the vaccine. 
Although the primary reason for HPV vaccination of 
pre-adolescent girls is to protect them from long-term 
risks, rather than to prevent immediate harm to others, 
it is justified to make HPV vaccination routine in Gha-
na. The available data21 makes this imperative - 4 in 10 
Ghanaian females 15–19 years have had sex. By 20 
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years, 83% of women have had sex. Of this group, 4 in 
10 women 12 – 24 years have had more than one sexu-
al partner.
Sexual coercion is common with 1 in 4 sexually expe-
rienced young women having ever been forced against 
their will to have sexual intercourse. Twelve per cent
of women were forced into their first sexual experi-
ence.
Since HPV infection is an STI, making it voluntary 
may be ineffective because parents who choose to let 
their daughters have the vaccine may be seen as having 
promiscuous daughters. This would result in the stig-
matization of HPV vaccination. If it is routine, howev-
er, there will be no stigma attached to getting the vac-
cine and the majority of girls would be immunized. 
However, it is important that before routine vaccination 
against HPV is embarked upon in Ghana, information, 
education and communication on the need to reduce 
cervical cancer through HPV vaccination should be 
done. In addition, though routine, informed consent 
should still be sought and there should be guidelines in 
place for those who may choose to opt out.
Although Ghana has a strong case for routine HPV 
vaccination, it simply cannot afford it. Neither is it 
feasible for the National Health Insurance Scheme 
(NHIS) in Ghana to cover the cost of routine HPV vac-
cination with its current funding. What is feasible, 
however, is to make it a part of the Expanded Program 
of Immunisation (EPI) and source for funding from 
The Global Alliance for Vaccines and Immunization 
(GAVI).
Since The GAVI Alliance has decided to include the 
HPV vaccine among its next priorities,22 Ghana 
could source for funding from The GAVI Alliance. In
addition, special pricing from the pharmaceutical com-
panies for poor countries23 and contribution from donor 
partners can provide substantial support in obtaining 
the vaccine. 
There is the need for some preparatory activities before 
the introduction of routine HPV vaccination. This 
should include information, education and communica-
tion on HPV and cervical cancer, advocacy, training 
and pharmacovigilance. Potential barriers should be 
identified so that the necessary steps can be taken in 
addressing them. This has been useful in other coun-
tries. For example, in a South African study investigat-
ing the key barriers and challenges to the introduction 
of HPV vaccination, the findings, not only identified 
these barriers and challenges. One particular finding of
note was that marketing the HPV vaccine as preventing 
cervical cancer rather than an STI was unlikely to be 
opposed.  The findings were also important in inform-
ing policy development of programs to support HPV 
vaccination in South Africa and other African coun-
tries.24
CONCLUSION 
Cervical cancer remains an important public health 
problem in developing countries where over 80% of 
the global burden occurs annually but screening has 
been largely ineffective.  Evidence so far indicates that 
the vaccines are both safe and efficacious. The ACIP 
recommends routine vaccination of females aged 11-12 
years. This can be started at 9 years with a catch-up 
vaccination of females aged 13-26 years. This is a poli-
cy which can be justifiably adopted in Ghana. 
Parental autonomy can be preserved with judicious 
exemptions for those who decline the vaccine on reli-
gious and philosophical grounds. This promotes public 
health without trampling parental authority. Routine 
HPV vaccination confers several benefits to individuals 
and society by preventing HPV infection. Instead of 
causing harm; it reduces harm by preventing the devel-
opment of about 70% of cervical cancers and removing 
the negative physical and psychological impact of a 
cervical cancer diagnosis. It also has the potential to 
reduce the disparities in cervical cancer rates and its 
cost effectiveness will ensure considerable cost savings 
in terms of the money spent on diagnosis and treat-
ment. 
Consequently, the HPV vaccine is an important public 
health landmark and achievement in women’s health 
that must be heralded, especially in developing coun-
tries where the bulk of the disease and death occur. 
With the availability of the HPV vaccines, we have the 
potential to prevent thousands of new cases of cervical 
cancer every year and HPV vaccination with cervical 
cancer screening makes cervical cancer the most pre-
ventable form of cancer.
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